MMP2 and neoplasm: In addition, the downregulation of CRIM1 and c-MET can affect the expression of MMP2/9 (matrix metalloproteinase 2/9, an enzyme active in the degradation of the extracellular matrix), thereby reducing the impact of matrix degradation products in the tumor microenvironment [27,28,86].